Keith M Channon Selected Research

CC Chemokines

12/2015	Hydrodynamic Gene Delivery of CC Chemokine Binding Fc Fusion Proteins to Target Acute Vascular Inflammation In Vivo.
10/2006	Membrane-bound CC chemokine inhibitor 35K provides localized inhibition of CC chemokine activity in vitro and in vivo.
8/2005	Gene transfer of a broad spectrum CC-chemokine inhibitor reduces vein graft atherosclerosis in apolipoprotein E-knockout mice.
10/2004	Broad-spectrum CC-chemokine blockade by gene transfer inhibits macrophage recruitment and atherosclerotic plaque formation in apolipoprotein E-knockout mice.
1/2003	Adenoviral-mediated delivery of a viral chemokine binding protein blocks CC-chemokine activity in vitro and in vivo.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Keith M Channon Research Topics

Disease

47	Atherosclerosis 01/2023 - 01/2003
32	ST Elevation Myocardial Infarction 03/2024 - 05/2011
31	Inflammation (Inflammations) 10/2022 - 01/2003
22	Cardiovascular Diseases (Cardiovascular Disease) 01/2023 - 12/2009
18	Coronary Artery Disease (Coronary Atherosclerosis) 01/2020 - 04/2002
18	Vascular Diseases (Vascular Disease) 01/2017 - 09/2003
17	Infarction (Infarctions) 11/2023 - 10/2013
14	Heart Failure 01/2024 - 10/2003
14	Atherosclerotic Plaque (Atheroma) 01/2021 - 11/2003
13	Myocardial Infarction 01/2024 - 05/2011
12	Phenylketonurias (Phenylketonuria) 01/2023 - 07/2004
9	Thrombosis (Thrombus) 01/2024 - 12/2007
8	Reperfusion Injury 01/2023 - 12/2010
8	Atrial Fibrillation 01/2022 - 09/2005
7	Hyperplasia 11/2022 - 10/2002
6	Myocardial Ischemia (Ischemic Heart Diseases) 01/2023 - 10/2013
5	Edema (Dropsy) 01/2023 - 05/2011
5	Fibrosis (Cirrhosis) 01/2023 - 05/2008
5	COVID-19 10/2022 - 10/2020
5	Peritonitis 01/2022 - 10/2006
5	Aortic Aneurysm (Aneurysm, Aortic) 01/2021 - 03/2015
5	Ischemia 01/2021 - 07/2007
5	Insulin Resistance 01/2020 - 02/2008
5	Diabetes Mellitus 01/2016 - 04/2002
4	Cardiac Arrhythmias (Arrythmia) 01/2023 - 11/2020
4	Obesity 12/2021 - 02/2008
4	Coronary Disease (Coronary Heart Disease) 10/2020 - 10/2004
4	Vascular Remodeling 01/2018 - 08/2006
4	Bradycardia 11/2017 - 02/2007
4	Vascular System Injuries 06/2015 - 04/2007
4	Hypoxia (Hypoxemia) 09/2014 - 04/2005
4	Hypertrophy 03/2013 - 05/2008
3	Acute Coronary Syndrome 03/2024 - 11/2019
3	Heart Arrest (Cardiac Arrest) 01/2024 - 01/2021
3	Cardiomegaly (Heart Hypertrophy) 01/2023 - 05/2008
3	Disease Progression 11/2022 - 03/2007
3	Ventricular Tachycardia 07/2022 - 01/2020
3	Pain (Aches) 01/2022 - 09/2008
3	Aneurysm (Aneurysms) 01/2021 - 04/2011
3	Infections 11/2020 - 12/2004
3	Rupture 01/2018 - 03/2015
3	Mitochondrial Diseases (Mitochondrial Disease) 01/2018 - 12/2008
3	Type 2 Diabetes Mellitus (MODY) 06/2015 - 03/2007
3	Parkinson Disease (Parkinson's Disease) 05/2015 - 12/2008
3	Pulmonary Hypertension 09/2014 - 04/2005
3	Wounds and Injuries (Trauma) 05/2014 - 09/2002
3	Neointima 11/2013 - 11/2003
3	Hypertension (High Blood Pressure) 12/2010 - 02/2007
2	Stroke (Strokes) 01/2023 - 08/2005
2	Necrosis 01/2023 - 01/2017

Drug/Important Bio-Agent (IBA)

34	sapropterin (tetrahydrobiopterin)FDA Link 05/2023 - 03/2004
26	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2020 - 03/2004
20	Superoxides (Superoxide)IBA 12/2021 - 04/2002
19	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022 - 09/2003
18	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 06/2013 - 04/2002
17	GTP Cyclohydrolase (GTP Cyclohydrolase I)IBA 01/2022 - 03/2004
14	Nitric Oxide Synthase (NO Synthase)IBA 01/2023 - 04/2002
13	Biomarkers (Surrogate Marker)IBA 11/2023 - 09/2014
13	EnzymesIBA 05/2023 - 03/2004
13	NADPH Oxidases (NAD(P)H oxidase)IBA 01/2022 - 04/2002
12	Apolipoproteins E (ApoE)IBA 01/2023 - 03/2004
11	Proteins (Proteins, Gene)FDA Link 01/2018 - 10/2004
11	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2017 - 04/2008
9	GadoliniumIBA 01/2023 - 05/2011
9	Angiotensin IIIBA 01/2021 - 02/2006
8	TroponinIBA 03/2024 - 09/2015
8	ChemokinesIBA 03/2015 - 01/2003
7	ApolipoproteinsIBA 12/2014 - 10/2004
6	AntioxidantsIBA 12/2021 - 07/2007
5	omega-Chloroacetophenone (Mace)IBA 01/2023 - 11/2011
5	CC ChemokinesIBA 12/2015 - 01/2003
5	BiopterinsIBA 03/2012 - 12/2007
4	Neuropeptide YIBA 01/2022 - 08/2013
4	VaccinesIBA 01/2022 - 10/2011
4	Phosphotransferases (Kinase)IBA 01/2022 - 01/2013
4	ZymosanIBA 01/2022 - 08/2011
4	C-Reactive ProteinIBA 01/2022 - 09/2009
4	CalciumIBA 01/2022 - 11/2019
4	Adenosine (Adenocard)FDA LinkGeneric 06/2021 - 01/2017
4	LDL CholesterolIBA 01/2017 - 04/2008
3	MicroRNAs (MicroRNA)IBA 11/2023 - 09/2013
3	Guanosine Triphosphate (GTP)IBA 05/2023 - 06/2013
3	RNA (Ribonucleic Acid)IBA 10/2022 - 06/2015
3	Insulin (Novolin)FDA Link 01/2020 - 08/2011
3	LipidsIBA 11/2019 - 05/2010
3	AdiponectinIBA 06/2015 - 06/2013
3	Chemokine CX3CL1IBA 12/2014 - 11/2003
3	Protein Isoforms (Isoforms)IBA 06/2014 - 02/2006
3	erucylphosphocholineIBA 05/2014 - 12/2010
3	LigandsIBA 06/2012 - 10/2007
3	ferric oxide (iron oxide)IBA 06/2012 - 10/2007
3	NADP (NADPH)IBA 01/2012 - 01/2008
3	Nitric Oxide Synthase Type I (Neuronal Nitric Oxide Synthase)IBA 05/2010 - 10/2003

Therapy/Procedure

27	Percutaneous Coronary Intervention 01/2023 - 07/2007
19	Stents 01/2023 - 10/2002
13	Therapeutics 10/2022 - 05/2007
10	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 11/2022 - 05/2007
3	Drug-Eluting Stents 06/2015 - 10/2004
2	Patient Readmission 01/2024 - 01/2023
2	Secondary Prevention 01/2023 - 03/2014